Atlas Trials

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

Clinical trial NCT05142241 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05142241
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Malignant Solid Neoplasm
Start date
2022-07-11
Primary completion
2025-09-26
Enrollment
14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.